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journal homepage: http: / /www.pediatr -neonatol .comEDITORIALNasal CPAP or INSURE for RDSNeonatal respiratory distress syndrome (RDS) is a syndrome in
premature infants caused by surfactant insufficiency and
structural immaturity in the lungs.1 RDS influences about 1% of
newborn infants and is the leading cause of death in preterm
infants. The incidence decreases with advancing gestational
age, from about 50% in babies born at 26e28 weeks, to about
25% at 30e31 weeks.2 Although surfactant replacement suc-
cessfully improves the survival of premature infants with RDS,
these premature infants may develop bronchopulmonary
dysplasia (BPD) because of less developed or more damaged
lungs.3 BPD continues to rise with the increasing rates of pre-
maturity, although there has been a great reduction in the
mortality and morbidity from RDS. Eighty-five percent of
extremely low birth weight premature infants develop BPD.
Preterm infants with BPD are at increased risk of death,
rehospitalization, and acute respiratory symptoms requiring
therapy. Therefore, recent researches have focused on the
efforts to prevent this complication.
TheAmericanAcademyofPediatrics strongly recommends
that: (1) preterm infants born before 30weeks’ gestation and
in need ofmechanical ventilation due to severeRDS should be
given surfactant after initial stabilization; and (2) that
continuouspositiveairwaypressure (CPAP) immediately after
birth with selective surfactant administration be used as an
alternative to routine intubation with prophylactic or early
surfactant administration in preterm infants.4 The INSURE
technique, which consists of an INtubation-SURfactant-
Extubation sequence, has been reported to reduce the need
for mechanical ventilation, the duration of respiratory sup-
port, and the need for surfactant replacement in preterm
infants with RDS. However, previous studies on the INSURE
strategy showed inconstant results.5
In this issue of Pediatrics and Neonatology, Nakhshab
et al6 investigated the effects of the INSURE strategy on the
requirement of mechanical ventilation, mortality, and mor-
bidities in moderately preterm infants. In this study, 60 in-
fants with a gestational age 27e35 weeks who required
supplemental oxygen at a fraction of inspired oxygen (FiO2)
0.4 to maintain oxygen saturation in the range of 88e95%
were randomly assigned to either INSURE or nasal CPAP
alone. The results showed that INSURE applied at amean age
of 5.1 hours exhibited comparable effects on the rate ofhttp://dx.doi.org/10.1016/j.pedneo.2014.12.002
1875-9572/Copyright ª 2015, Taiwan Pediatric Association. Published bmortality and BPD and the need for mechanical ventilation
compared with nasal CPAP alone. The first limitation of this
study is the relatively small sample size and this might affect
the power to find smaller differences between the study
groups. The second limitation is the lack of blinding. Com-
plete blinding was not easy in this study because of the
requirement of separate dosing teams to administer surfac-
tant and the difficulties in recognizing the improvement in
oxygenation after the administration of surfactant. The third
limitation is the significantly lower mean birth weight in the
INSURE group than that in the nasal CPAP group. The differ-
ences in birth weight might explain the absence of beneficial
effects in the INSURE group.
Although this study has several limitations, it empha-
sizes the fact that prevention of BPD requires a multifac-
eted strategy. The results of many respiratory strategies for
RDS are confusing and the evidence does not provide the
overall view. The responsibility is on the clinicians to select
the correct mode of treatment and enhance treatment
efficacy and safety for individual infants. Further re-
searches are needed to answer several questions on the
short term and long term outcomes of various respiratory
supports presently being practiced in neonatal intensive
care units.
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